Companies · Biotechnology

Surrozen, Inc./DE

SOUTH SAN FRANCISCO · Biotechnology

Diligence memoA one-page analyst read on Surrozen, Inc./DE — recommendation, valuation, rhythm, risks.
$269.4M
Total raised · real
2
Rounds
0.4×
Latest step-up
Top 3%
Sector rank · raised
Series D+
Latest stage · inferred · Wed Mar 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Surrozen, Inc./DE looks fair against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.74× the median modeled value of Series D+ Biotechnology companies in 2025–2027 (33 peers) — value vs value, same stage and era.
  • Within the normal band (74% of peer median) for its niche.
Active
  • Last raise 15 mo ago; this sector typically re-raises about every 14 months.
  • Raising on or ahead of the sector's normal rhythm.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Surrozen, Inc./DE is one of 4291 Biotechnology companies tracked from SOUTH SAN FRANCISCO. By capital raised it ranks among the largest (ahead of 98% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
29
Investors (latest)
2021
Year incorporated
2025-03-26
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$1.3B$2.5B$3.8B$5.0BSeries D+ · 2024-04-04 Raised $193M (real) Modeled valuation $2.3B (est)$193M$2.3BSeries D+2024Series D+ · 2025-03-26 Raised $76M (real) Modeled valuation $658M (est)$76M$658MSeries D+2025+$76MCumulative $269M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series D+$193.0M · 2024
Series D+ extension$76.4M · 2025

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A, Series B, Series C — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 17%.

Modeled valuation trajectory
$657.8M
Base estimate est.
$346.4M
Conservative case
$840.3M
Upside case
$636.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series D+a $100M–$400M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series D+ · modeled $2.3B · 2024-04-042024Series D+ · modeled $657.8M · 2025-03-262025
Model inputs · modeled:benchmark-stage-stepup-v1
12%
Dilution assumption
Implied ownership sold in the financing.
68%
Survival probability
54% low · 75% high
1.39×/yr
Annual markup
1.56×/yr upside case
1.3 yr
Elapsed time used
1.3 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
12 mo
Avg between rounds
$276.4M/yr
Capital velocity
2.2 yr
On record since
2024
First round
2
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 37× above median
This company$269.4M
Sector median$7.2M
Latest round — vs other Series D+ rounds in sector (real $, this stage) 0.6× of median
This company$76.4M
Sector median$120.0M
Modeled value — vs sector median (estimate, all stages) 10× above median
This company$657.8M
Sector median$64.2M

Raised more than 98% of sector peers (real $). Modeled value above 85% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series D+) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #25 of 33.

This companyCohort peer
$100.0M$1.0B$10.0B$100.0M$1.0BCapital raised (log)Kriya Therapeutics, Inc. · Series D+ Raised $870.3M · modeled $2.5B (est)Pathos AI, Inc. · Series D+ Raised $365.0M · modeled $2.4B (est)Sensei Biotherapeutics, Inc. · Series D+ Raised $348.9M · modeled $2.2B (est)Odyssey Therapeutics, Inc. · Series D+ Raised $590.9M · modeled $1.7B (est)Rhodenergy An Environmental Co Corp · Series D+ Raised $250.0M · modeled $1.7B (est)Tectonic Therapeutic, Inc. · Series D+ Raised $333.1M · modeled $1.7B (est)Lumicell, Inc. · Series D+ Raised $331.1M · modeled $1.7B (est)MapLight Therapeutics, Inc. · Series D+ Raised $356.2M · modeled $1.5B (est)SAB Biotherapeutics, Inc. · Series D+ Raised $182.5M · modeled $1.4B (est)Immunic, Inc. · Series D+ Raised $514.4M · modeled $1.3B (est)Predictive Oncology Inc. · Series D+ Raised $280.1M · modeled $1.3B (est)Vascular Perfusion Solutions, Inc. · Series D+ Raised $154.9M · modeled $1.2B (est)Surrozen, Inc./DE (this company) Raised $269.4M · modeled $657.8M (est)Surrozen, Inc./DE
CompanyStageRaised · realValue · estvs peer med.
Kriya Therapeutics, Inc.Series D+$870.3M$2.5B2.79×
Pathos AI, Inc.Series D+$365.0M$2.4B2.70×
Sensei Biotherapeutics, Inc.Series D+$348.9M$2.2B2.53×
Odyssey Therapeutics, Inc.Series D+$590.9M$1.7B1.94×
Rhodenergy An Environmental Co CorpSeries D+$250.0M$1.7B1.89×
Tectonic Therapeutic, Inc.Series D+$333.1M$1.7B1.89×
Lumicell, Inc.Series D+$331.1M$1.7B1.89×
MapLight Therapeutics, Inc.Series D+$356.2M$1.5B1.65×
SAB Biotherapeutics, Inc.Series D+$182.5M$1.4B1.53×
Immunic, Inc.Series D+$514.4M$1.3B1.45×
Predictive Oncology Inc.Series D+$280.1M$1.3B1.42×
Vascular Perfusion Solutions, Inc.Series D+$154.9M$1.2B1.37×
Surrozen, Inc./DE this companySeries D+$269.4M$657.8M0.74×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series D+$193.0M2024-04-04$1.6B$2.3B90%
Series D+$76.4M2025-03-26$636.7M$657.8M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series D+$193.0M2024-04-04
    • First recorded raise — entered as Series D+.
    • 18 investors on this round.
  2. Series D+$76.4M2025-03-26
    • Raised 12 mo later, in step with the ~14 mo sector norm.
    • Round 2.5× smaller than the prior — bridge or down round.
    • 29 investors on this round.
Intelligence
2026 ~Q1
Modeled next raise · ~12mo cadence
$76.4M
Modeled next size est.range $76.4M$122.2M
0.4×
Last step-up
$276.4M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Craig Parker4 other2024-04
Anna J. Berkenblit, M.D.2024-04
Charles Williams2024-04
Christopher J. Chai2024-04
David J. Woodhouse, Ph.D.2024-04
Eric J. Bjerkholt2024-04
Mace J. Rothenberg, M.D.2024-04
Mary J. Haak-Frendscho, Ph.D.2024-04
Shao-Lee J. Lin, M.D., Ph.D.2024-04
Tim J. Kutzkey, Ph.D.2024-04
Yang J. Li, Ph.D.2025-03
Registry & provenance

Surrozen, Inc./DE is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1824893
SEC CIK
2021
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Aligos Therapeutics, Inc.BiotechnologySeries D+$282.2M$940.0Msame sector · same stage
Dewpoint Therapeutics, Inc.BiotechnologySeries D+$286.2M$437.6Msame sector · same stage
Iambic Therapeutics, Inc.BiotechnologySeries D+$240.9M$697.2Msame sector · same stage
Alumis Inc.BiotechnologySeries D+$240.0M$432.7Msame sector · same stage
Celcuity Inc.BiotechnologySeries D+$303.0M$691.3Msame sector · same stage
Lyra Therapeutics, Inc.BiotechnologySeries D+$236.6M$790.4Msame sector · same stage
Poseida Therapeutics, Inc.BiotechnologySeries D+$231.8M$369.6Msame sector · same stage
Amicus Therapeutics, Inc.BiotechnologySeries D+$314.5M$420.4Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Surrozen, Inc.BiotechnologySeries C$2.0B98%
SurgiBox Inc.BiotechnologyPre-Seed$750K84%
RegenX Science Inc.BiotechnologySeries A$62.3M84%
EdenRoc Sciences LLCBiotechnologySeries C$21.4M84%
ReGelTec, Inc.BiotechnologySeed$177.6M83%
Biorez, Inc.BiotechnologySeries A$89.0M83%
Resolute Science, Inc.BiotechnologySeed$4.7M82%
Vira Regen Inc.BiotechnologySeed$5.6M82%
Frequently asked
How much funding has Surrozen, Inc./DE raised?
Surrozen, Inc./DE has raised approximately $269.4M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Surrozen, Inc./DE's estimated valuation?
Provath's modeled valuation for Surrozen, Inc./DE is approximately $657.8M (modeled range $346.4M–$840.3M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Surrozen, Inc./DE at?
Surrozen, Inc./DE's latest modeled financing stage is Series D+. Its most recent recorded round closed around Wed Mar 26.
What does Surrozen, Inc./DE do and where is it based?
Surrozen, Inc./DE operates in the Biotechnology sector, based in SOUTH SAN FRANCISCO.
Explore related

See where Surrozen, Inc./DE sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Surrozen, Inc./DE, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.